|
|
||||||||


*
Department of Surgery, Duke University Medical Center, Durham, NC 27710; and
Department of Surgery, University of Virginia Health Sciences Center, Charlottesville, VA 22908
To investigate the ability of human dendritic cells (DC) to process and present multiple epitopes from the gp100 melanoma tumor-associated Ags (TAA), DC from melanoma patients expressing HLA-A2 and HLA-A3 were pulsed with gp100-derived peptides G9154, G9209, or G9280 or were infected with a vaccinia vector (Vac-Pmel/gp100) containing the gene for gp100 and used to elicit CTL from autologous PBL. CTL were also generated after stimulation of PBL with autologous tumor. CTL induced with autologous tumor stimulation demonstrated HLA-A2-restricted, gp100-specific lysis of autologous and allogeneic tumors and no lysis of HLA-A3-expressing, gp100+ target cells. CTL generated by G9154, G9209, or G9280 peptide-pulsed, DC-lysed, HLA-A2-matched EBV transformed B cells pulsed with the corresponding peptide. CTL generated by Vac-Pmel/gp100-infected DC (DC/Pmel) lysed HLA-A2- or HLA-A3-matched B cell lines pulsed with the HLA-A2-restricted G9154, G9209, or G9280 or with the HLA-A3-restricted G917 peptide derived from gp100. Furthermore, these DC/Pmel-induced CTL demonstrated potent cytotoxicity against allogeneic HLA-A2- or HLA-A3-matched gp100+ melanoma cells and autologous tumor. We conclude that DC-expressing TAA present multiple gp100 epitopes in the context of multiple HLA class I-restricting alleles and elicit CTL that recognize multiple gp100-derived peptides in the context of multiple HLA class I alleles. The data suggest that for tumor immunotherapy, genetically modified DC that express an entire TAA may present the full array of possible CTL epitopes in the context of all possible HLA alleles and may be superior to DC pulsed with limited numbers of defined peptides.
This article has been cited by other articles:
![]() |
J. Chapiro, S. Claverol, F. Piette, W. Ma, V. Stroobant, B. Guillaume, J.-E. Gairin, S. Morel, O. Burlet-Schiltz, B. Monsarrat, et al. Destructive Cleavage of Antigenic Peptides Either by the Immunoproteasome or by the Standard Proteasome Results in Differential Antigen Presentation J. Immunol., January 15, 2006; 176(2): 1053 - 1061. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Moran, M. Collier, K. P. McKinnon, N. L. Davis, R. E. Johnston, and J. S. Serody A Novel Viral System for Generating Antigen-Specific T Cells J. Immunol., September 1, 2005; 175(5): 3431 - 3438. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Murakami, N. Tokunaga, T. Waku, S. Gomi, S. Kagawa, N. Tanaka, and T. Fujiwara Antitumor Effect of Intratumoral Administration of Bone Marrow-Derived Dendritic Cells Transduced with Wild-Type p53 Gene Clin. Cancer Res., June 1, 2004; 10(11): 3871 - 3880. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Dadaglio, S. Morel, C. Bauche, Z. Moukrim, F. A. Lemonnier, B. J. Van den Eynde, D. Ladant, and C. Leclerc Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes Int. Immunol., December 1, 2003; 15(12): 1423 - 1430. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-L. Tso, A. Zisman, A. Pantuck, R. Calilliw, J. M. Hernandez, S. Paik, D. Nguyen, B. Gitlitz, P. I. Shintaku, J. de Kernion, et al. Induction of G250-targeted and T-Cell-mediated Antitumor Activity against Renal Cell Carcinoma Using a Chimeric Fusion Protein Consisting of G250 and Granulocyte/Monocyte-Colony Stimulating Factor Cancer Res., November 1, 2001; 61(21): 7925 - 7933. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ponnazhagan, G. Mahendra, D. T. Curiel, and D. R. Shaw Adeno-Associated Virus Type 2-Mediated Transduction of Human Monocyte-Derived Dendritic Cells: Implications for Ex Vivo Immunotherapy J. Virol., October 1, 2001; 75(19): 9493 - 9501. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Meyer zum Buschenfelde, J. Metzger, C. Hermann, N. Nicklisch, C. Peschel, and H. Bernhard The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells J. Immunol., August 1, 2001; 167(3): 1712 - 1719. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Mendiratta, G. Thai, N. K. Eslahi, N. M. Thull, M. Matar, V. Bronte, and F. Pericle Therapeutic Tumor Immunity Induced by Polyimmunization with Melanoma Antigens gp100 and TRP-2 Cancer Res., February 1, 2001; 61(3): 859 - 863. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |